The International Journal of Neuropsychopharmacology

Brief Report

Major depressive disorder, sleep EEG and agomelatine: an open-label study

Maria-Antonia Quera Salvaa1 c1, Bernard Vaniera1, Judith Laredoa2, Sarah Hartleya1, Florian Chapotota1, Catherine Moulina1, Frédéric Lofasoa1 and Christian Guilleminaulta3

a1 Sleep Unit, Raymond Poincaré Hospital, Garches, France

a2 Institut de Recherches Internationales Servier, Courbevoie, France

a3 Stanford Sleep Disorders Center, Stanford, CA, USA


This open study evaluates the effect of agomelatine, a melatonergic receptor agonist and 5-HT2C antagonist antidepressant, on sleep architecture in patients suffering from major depressive disorder. Fifteen outpatients with a baseline HAMD score xs2A7E20 were treated with 25 mg/d agomelatine for 42 d. Polysomographic studies were performed at baseline, day 7, day 14, and day 42. Sleep efficiency, time awake after sleep onset and the total amount of slow-wave sleep (SWS) increased at week 6. The increase of SWS was predominant during the first sleep cycle. The amount of SWS decreased throughout the first four sleep cycles from day 7 and delta ratio increased from day 14 onwards. No change in rapid eye movement (REM) latency, amount of REM or REM density was observed and agomelatine was well tolerated. In conclusion agomelatine improved sleep continuity and quality. It normalized the distribution of SWS sleep and delta power throughout the night.

(Received September 29 2006)

(Reviewed December 18 2006)

(Revised February 22 2007)

(Accepted March 18 2007)

(Online publication May 04 2007)